Dermapharm Holding SE (HAM:DMP) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE Debt-to-Equity?

Dermapharm Holding SE's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0 Mil. Dermapharm Holding SE's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0 Mil. Dermapharm Holding SE's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €582 Mil. Dermapharm Holding SE's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Dermapharm Holding SE's Debt-to-Equity or its related term are showing as below:

HAM:DMP' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.97 Med: 2 Max: 6.43
Current: 1.86

During the past 11 years, the highest Debt-to-Equity Ratio of Dermapharm Holding SE was 6.43. The lowest was 0.97. And the median was 2.00.

HAM:DMP's Debt-to-Equity is ranked worse than
93.73% of 845 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs HAM:DMP: 1.86

Dermapharm Holding SE Debt-to-Equity Historical Data

The historical data trend for Dermapharm Holding SE's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE Debt-to-Equity Chart

Dermapharm Holding SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.99

1.89

1.17

0.97

2.00

Dermapharm Holding SE Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-	2.11	-	2.00	-

Competitive Comparison of Dermapharm Holding SE's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dermapharm Holding SE's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's Debt-to-Equity falls into.

Dermapharm Holding SE Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Dermapharm Holding SE's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(116.43	+	963.958)	/	539.207
	=	2.00

Dermapharm Holding SE's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	581.906
	=	0.00

Dermapharm Holding SE (HAM:DMP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Dermapharm Holding SE Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Dermapharm Holding SE (HAM:DMP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (HAM:DMP) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

0A5J:UK DMP:Germany

Address

Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031

Website

https://www.dermapharm.de

Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs and natural remedies. Its portfolio of products includes cosmetics, nutritional supplements and diet and medical devices. Business operating segments include Branded pharmaceuticals and other healthcare products which drive key revenue, Herbal extracts and Parallel import business. Branded pharmaceuticals and other healthcare products focus on the development, manufacturing and marketing of branded pharmaceuticals and other healthcare products. Herbal extracts include the manufacturing of phytopharmaceuticals, nutraceuticals and cosmetics products. Parallel import brands business operates under the AxiCorp brand.

Dermapharm Holding SE (HAM:DMP) Headlines

No Headlines